Watson’s fentanyl buccal tablets C-II product is a generic version of Cephalon’s Fentora C-II (fentanyl buccal tablet) which is indicated only for the treatment of breakthrough pain in opioid tolerant patients with cancer.
In its notice letter to Cephalon, Watson contends that US patents of the product are invalid, unenforceable and/or will not be infringed by Watson’s manufacture, use or sale of the product described in its abbreviated new drug application (ANDA). Based on available information, Watson believes it may be the first applicant to file an ANDA for Fentora containing a paragraph IV certification under the provisions of the Hatch-Waxman Act and, should its product be approved, may be entitled to 180 days of generic market exclusivity.